Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose

Chemical Research in Toxicology

Volumn 21, Issue 9, 2008, Pages 1814-1822

  Obach, R Scott ^a   Kalgutkar, Amit S ^a   Soglia, John R ^a   Zhao, Sabrina X ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENOXAPROFEN; BUSPIRONE; CARBAMAZEPINE; DICLOFENAC; DIPHENHYDRAMINE; FELBAMATE; IBUPROFEN; INDOMETACIN; MELOXICAM; NEFAZODONE; PARACETAMOL; PAROXETINE; PROPRANOLOL DERIVATIVE; RALOXIFENE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SIMVASTATIN; SUDOXICAM; THEOPHYLLINE; TIENILIC ACID;

ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG BINDING; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; LIVER TOXICITY;

ACETAMINOPHEN; BINDING SITES; BUSPIRONE; CARBAMAZEPINE; DICLOFENAC; DIPHENHYDRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HEPATOCYTES; HUMANS; INDOMETHACIN; MICROSOMES, LIVER; MOLECULAR STRUCTURE; PAROXETINE; PROPRANOLOL; RALOXIFENE; SIMVASTATIN; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZINES; THIAZOLES; TICRYNAFEN; TOXICITY TESTS; TRIAZOLES;

EID: 53549100467     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx800161s     Document Type: Article

References (61)

1. Kramer, J. A., Sagartz, J. E., and Morris, D. L. (2007) The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat. Rev. Drug Discovery 6, 636-649.
2. Beaune, P., Dansette, P. M., Mansuy, D., Kiffel, L., Finck, M., Amar, C.,Leroux, J. P., and Homberg, J. C. (1987) Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc. Natl. Acad. Sci. U.S.A. 84, 551-555.
3. Murphy, E. J., Davern, T. J., Shakil, A. O., Shick, L., Masharani, U., Chow, H., Freise, C.,Lee, W. M., and Bass, N. M. (2000) Troglita-zone-induced fulminant hepatic failure. Acute Liver Failure Study Group. Dig. Dis. Sci. 45, 549-553.
4. Stewart, D. E. (2002) Hepatic adverse reactions associated with nefazodone. Can. J. Psychiatry 47, 375-377.
5. Uetrecht, J. P. (2000) Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions? Curr. Drug Metab. I, 133-141.
6. Shenton, J. M., Chen, J., and Uetrecht, J. P. (2004) Animal models of idiosyncratic drug reactions. Chem.-Biol. Interact. 150, 53-70.
7. Abboud, G., and Kaplowitz, N. (2007) Drug-induced liver injury. Drug Saf. 30, 277-294.
8. Biour, M., Poupon, R., Grange, J. D., and Chazouilleres, O. (2000) Drug-induced hepatotoxicity. The 13th updated edition of the bibliographic database of drug-related liver injuries and responsible drugs. Gastroenterol. Clin. Biol. 24, 1052-1091.
9. Kaplowitz, N. (2004) Acetaminophen hepatoxicity: What do we know, what don't we know, and what do we do next? Hepatology 40, 23-26.
10. Boelsterli, U. A. (2003) Diclofenac-induced liver injury: A paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. 192, 307-322.
11. Liquori, M. J., and Waring, J. F. (2006) Investigations toward enhanced understanding of hepatic idiosyncratic drug reactions. Exp. Opin. Drug Metab. Toxicol. 2, 835-846.
12. Xu, J. J., Diaz, D., and O'Brien, P. J. (2004) Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem-Biol. Interact. 150, 115-128.
13. Miller, E. C.,and Miller, J. A. (1947) The presence and significance of bound aminoazo dyes in the liver of rats fed p-dimethylaminoa-zobenzene. Cancer Res. 7, 468-480.
14. Mitchell, J. R., Jollow, D. J., Potter, W. Z., Davis, D. C.,Gillette, J. R., and Brodie, B. B. (1973) Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol. Exp. Ther. 187, 185-194.
15. Nelson, S. D., Mitchell, J. R., Timbrell, J. A., Snodgrass, W. R., and Corcoran, G. B. (1976) Isoniazid and iproniazid: Activation of metabolites to toxic intermediates in man and rat. Science 193, 901-903.
16. Evans, D. C.,Watt, A. P., Nicoll-Griffith, D. A., and Baillie, T. A. (2004) Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16.
17. Masubuchi, N., Makino, C.,and Murayama, N. (2007) Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: Correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem. Res. Toxicol. 20, 455-464.
18. Kalgutkar, A. S., Gardner, I., Obach, R. S., Shaffer, C. L., Callegari, E., Henne, K. R., Mutlib, A. E., Dalvie, D. K., Lee, J. S., Nakai, Y., O'Donnell, J. P., Boer, J., and Harriman, S. P. (2005) A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 6, 161-225.
19. James, L. P., Mayeux, P. R., and Hinson, J. A. (2003) Acetaminophen-induced hepatotoxicity. Drug Metab. Dispos. 31, 1499-1506.
20. Halsey, J. P., and Cardoe, N. (1982) Benoxaprofen: Side-effect profile in 300 patients. Br. Med. J. (Clin. Res. Ed.) 284, 1365-1368.
21. Pirmohamed, M., Kitteringham, N. R., Breckenridge, A. M., and Park, B. K. (1992) Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity. Br. J. Clin. Pharmacol. 33, 183-186.
22. Aithal, G. P., and Day, C. P. (2007) Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin. Liver Dis. 11, 563-575.
23. O'Neil, M. G., Perdun, C. S., Wilson, M. D., McGown, S. T., and Patel, S. (1996) Felbamate-associated fatal acute hepatic necrosis. Neurology 46, 1457-1459.
24. Fenech, F. F., Bannister, W. H., and Grech, J. L. (1967) Hepatitis with biliverdinaemia in association with indomethacin therapy. Br. Med. J. 3, 155-156.
25. García-Pando, A. C.,Garcia del Pozo, J., Sánchez, A. S., Martín, A. V., Rueda de Castro, A. M., and Lucena, M. I. (2002) Hepatotoxicity associated with the new antidepressants. J. Clin. Psychiatry 63, 135-137.
26. Nelson, S. D. (1982) Metabolic activation and drug toxicity. J. Med. Chem. 25, 753-765.
27. Lecoeur, S., Andre, C.,and Beaune, P. H. (1996) Tienilic acid-induced autoimmune hepatitis: Anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol. Pharmacol. 50, 326-333.
28. Goldkind, L., and Laine, L. (2006) A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: Lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf. 15, 213-220.
29. Choi, S. (2003) Nefazodone (serzone) withdrawn because of hepatotoxicity. CMAJ 169, 1187.
30. Neuberger, J., and Williams, R. (1989) Immune mechanisms in tienilic acid associated hepatotoxicity. Gut 30, 515-519.
31. Dahlin, D. C.,Miwa, G. T., Lu, A. Y., and Nelson, S. D. (1984) N-acetyl-p-benzoquinone imine: A cytochrome P-450-mediated oxidation product of acetaminophen. Proc. NatL Acad. Sci. U.S.A. 81,1327-1331.
32. Qiu, Y., Burlingame, A. L., and Benet, L. Z. (1998) Mechanisms for covalent binding of benoxaprofen glucuronide to human serum albumin. Studies by tandem mass spectrometry. Drug Metab. Dispos. 26, 246-256.
33. Dong, J. Q., Liu, J., and Smith, P. C. (2005) Role of benoxaprofen and flunoxaprofen acyl glucuronides in covalent binding to rat plasma and liver proteins in vivo. Biochem. Pharmacol. 70, 937-948.
34. Ju, G., and Uetrecht, J. P. (1999) Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. J. Pharmacol. Exp. Ther. 288, 51-56.
35. Wolkenstein, P., Tan, C.,Lecoeur, S., Wechsler, J., Garcia-Martin, N., Charue, D., Bagot, M., and Beaune, P. (1998) Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin. Chem.-Biol. Interact. 113, 39-50.
36. Tang, W., Steams, R. A., Wang, R. W., Chiu, S. H., and Baillie, T. A. 1999a Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem. Res. Toxicol. 12, 192-199.
37. Kretz-Rommel, A., and Boelsterli, U. A. (1993) Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. Toxicol. Appl. Pharmacol. 120, 155-161.
38. Thompson, C. D., Kinter, M. T., and Macdonald, T. L. (1996) Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropional-dehyde and 2-phenylpropenal: Putative reactive metabolites of fel-bamate. Chem. Res. Toxicol. 9, 1225-1229.
39. Thompson, C. D., Gulden, P. H., and Macdonald, T. L. (1997) Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration. Chem. Res. Toxicol. 10, 457-462.
40. Walker, G. S., Atherton, J., Bauman, J., Kohl, C.,Lam, W., Reily, M., Lou, Z., and Mutlib, A. (2007) Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy. Chem. Res. Toxicol. 20, 876-886.
41. Ju, C.,and Uetrecht, J. P. (1998) Oxidation of a metabolite of indomethacin (desmethyldeschlorobenzoylindomethacin) to reactive intermediates by activated neutrophils, hypochlorous acid, and the myeloperoxidase system. Drug Metab. Dispos. 26, 676-680.
42. Kalgutkar, A. S., Vaz, A. D., Lame, M. F., Henne, K. R., Soglia, J., Zhao, S. X., Abramov, Y. A., Lombardo, F., Collin, C.,Hendsch, Z. S., and Hop, C. E. (2005) Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab. Dispos. 33, 243-253.
43. Hobbs, D. C.,and Twomey, T. M. (1977) Metabolism of sudoxicam by the rat, dog, and monkey. Drug Metab. Dispos. 5, 75-81.
44. Lopez-Garcia, M. P., Dansette, P. M., and Mansuy, D. (1994) Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: Inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 33, 166-175.
45. Koenigs, L. L., Peter, R. M., Hunter, A. P., Haining, R. L., Rettie, A. E., Friedberg, T., Pritchard, M. P., Shou, M., Rushmore, T. H., and Trager, W. F. (1999) Electrospray ionization mass spectrometric analysis of intact cytochrome P450: Identification of tienilic acid adducts to P450 2C9. Biochemistry 38, 2312-2319.
46. Lecoeur, S., Andre, C.,and Beaune, P. H. (1996) Tienilic acid-induced autoimmune hepatitis: Anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol Pharmacol 50, 326-333.
47. Leone, A. M., Kao, L. M., McMilHan, M. K., Nie, A. Y., Parker, J. B., Kelley, M. F., Usuki, E., Parkinson, A., Lord, P. G., and Johnson, M. D. (2007) Evaluation of felbamate and other antiepilepric drug toxicity potential based on hepatic protein covalent binding and gene expression. Chem. Res. Toxicol. 20, 600-608.
48. El Mouelhi, M., Ruelius, H. W., Fenselau, C.,and Dulik, D. M. (1987) Species-dependent enantioselective glucuronidation of three 2-aryl-propionic acids. Naproxen, ibuprofen, and benoxaprofen. Drug Metab. Dispos. 15, 767-772.
49. Baldacci, A., Prost, F., and Thormann, V. (2004) Identification of diphenhydramine metabolites in human urine by capillary electrc-phoresis-ion trap-mass spectrometry. Electrophoresis 25,1607-1614.
50. Pritchard, J. F., Schneck, D. W., and Hayes, A. H., Jr. (1980) The inhibition of rat hepatic microsomal propranolol metabolism by a covalently bound reactive metabolite. Res. Commun. Chem. Pathol. Pharmacol. 27, 211-222.
51. Narimatsu, S., Arai, T., Watanabe, T., Masubuchi, Y., Horie, T., Suzuki, T., Ishikawa, T., Tsutsui, M., Kumagai, Y., and Cho, A. K. (1997) Covalent binding of a reactive metabolite derived from propranolol and its active metabolite 4-hydroxypropranoIol to hepatic microsomal proteins of the rat Chem. Res. Toxicol. 10, 289-295.
52. Chen, Q., Ngui, J. S., Doss, G. A., Wang, R. W., Cai, X., DiNinno, F. P., Blizzard, T. A., Hammond, M. L., Stearns, R. A., Evans, D. C.,Baillie, T. A., and Tang, W. (2002) Cytochrome P450 3A4-mediated bioactivation of raloxifene: Irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol. 15, 907-914.
53. Jeong, E. J., Liu, Y., Lin, H., and Hu, M. (2005) Species- and disposition model-dependent metabolism of raloxifene in gut and liver role of UGT1A10. Drug Metab. Dispos. 33, 785-794.
54. Kemp, D. C.,Fan, P. W., and Stevens, J. C. (2002) Characterization of raloxifene glucuronidation in vitro: Contribution of intestinal metabolism to presystemic clearance. Drug Metab. Dispos. 30, 694-700.
55. Busch, U., Schmid, J., Heinzel, G., Schmaus, H., Baierl, J., Huber, C.,and Roth, W. (1998) Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab. Dispos. 26, 576-584.
56. Mayol, R. F., Cole, C. A., Luke, G. M., Colson, K. L., and Kerns, E. H. (1994) Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab. Dispos. 22, 304-311.
57. Zhao, S. X., Dalvie, D. K., Kelly, J. M., Soglia, J. R., Frederick, K. S., Smith, E. B., Obach, R. S., and Kalgutkar, A. S. (2007) NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: Identification of an electrophilic quinone metabolite of paroxetine. Chem. Res. Toxicol. 20, 1649-1657.
58. Armitage, J. (2007) The safety of statins in clinical practice. Lancet 370, 1781-1790.
59. Shin, N. Y., Liu, Q., Starrier, S. L., and Liebler, D. C. (2007) Protein targets of reactive electrophiles in human liver microsomes. Chem. Res. Toxicol. 20, 859-867.
60. Liebler, D. C. (2007) Protein damage of reactive electrophiles. Targets and consequences. Chem. Res. Toxicol. 21, 117-128.
61. Qiu, Y., Burlingame, A. L., and Benet, L. Z. (1998) Mechanisms for covalent binding of benoxaprofen glucuronide to human serum albumin. Studies by tandem mass spectrometry. Drug Metab. Dispos. 26, 246-256.